Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

1,769JPY
18 Apr 2014
Price Change (% chg)

¥16 (+0.91%)
Prev Close
¥1,753
Open
¥1,750
Day's High
¥1,770
Day's Low
¥1,747
Volume
1,185,500
Avg. Vol
3,033,494
52-wk High
¥2,014
52-wk Low
¥1,525

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company has two business segments. The Daiichi Sankyo Group segment is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and... (more)

Overall

Beta: 0.69
Market Cap (Mil.): ¥1,242,897.00
Shares Outstanding (Mil.): 709.01
Dividend: 30.00
Yield (%): 3.42

Financials

  4568.T Industry Sector
P/E (TTM): 13.73 33.23 33.33
EPS (TTM): 127.67 -- --
ROI: 6.85 19.68 18.94
ROE: 10.01 20.37 19.69
Search Stocks

India's Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats

TOKYO/MUMBAI - India's Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co , and got Ranbaxy India-made drugs barred from the United States. | Video

07 Apr 2014

UPDATE 4-India's Sun Pharma to buy struggling Ranbaxy for $3.2 bln as Daiichi Sankyo retreats

* Investors to get 0.8 Sun Pharma share per Ranbaxy share

07 Apr 2014

Nikkei falls to 1-week low, SoftBank dives on selloff in U.S. tech stocks

* SoftBank dives in wake of selloff in U.S. tech stocks * Daiichi Sankyo soars after Sun Pharma buys Indian unit Ranbaxy * U.S. jobs data positive but overshadowed by Wall Street slide By Ayai Tomisawa TOKYO, April 7 - Japan's Nikkei share average tumbled to a one-week low on Monday morning after a slide on Wall Street overshadowed encouraging U.S. jobs data, and index heavyweight SoftBank Corp dived in the wake of a sell-off in U.S. tech names. Traders said SoftBa

06 Apr 2014

Daiichi Sankyo says Sun Pharma to buy Indian unit Ranbaxy

TOKYO, April 7 - Japan's Daiichi Sankyo Co Ltd said on Monday Sun Pharmaceutical Industries Ltd will buy its Indian unit Ranbaxy Laboratories Ltd , creating the world's fifth-largest speciality generics company.

06 Apr 2014

Daiichi Sankyo pledges bold action on Ranbaxy production problems

TOKYO - Japan's Daiichi Sankyo Co Ltd said it would step up support of Indian drugmaking arm Ranbaxy Laboratories Ltd and send personnel to help resolve problems at a factory that U.S. regulators have banned from supplying pharmaceutical ingredients.

31 Jan 2014

Daiichi Sankyo pledges bold action on Ranbaxy production problems

TOKYO, Jan 31 - Japan's Daiichi Sankyo Co Ltd said it would step up support of Indian drugmaking arm Ranbaxy Laboratories Ltd and send personnel to help resolve problems at a factory that U.S. regulators have banned from supplying pharmaceutical ingredients.

31 Jan 2014

Update-Moody's: FDA Prohibition Order on Ranbaxy' Toansa Plant Is Credit Negative for Daiichi Sankyo

For the full text of this story please click the following link:

28 Jan 2014

UPDATE 3-India's Ranbaxy hit by FDA product ban at 4th Indian plant

WASHINGTON/MUMBAI, Jan 23 - Indian drugmaker Ranbaxy Laboratories Ltd faces long delays and high costs in launching big-selling generic drugs in the United States after products from a fourth plant were banned from entering its main market due to manufacturing violations.

24 Jan 2014

Nikkei drops to 1-month low as China PMI impact drags; Daiichi Sankyo tumbles

* Daiichi Sankyo falls on U.S. FDA's ban on Ranbaxy * Nitto Denko soars on strong monthly sales, Citi's target hike * Eyes on U.S. Fed's policy meeting - analyst By Ayai Tomisawa TOKYO, Jan 24 - Japan's Nikkei share average dropped to a one-month low on Friday morning as weak Chinese manufacturing activity data continued to hurt sentiment - keeping the market risk-averse before the U.S. Federal Reserve's policy-setting meeting next week. Friday's notable losers inc

23 Jan 2014

New Daiichi drug succeeds in major study; set to face rivals

DALLAS - A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.

19 Nov 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks